![Between the Bells artwork](https://is4-ssl.mzstatic.com/image/thumb/Podcasts123/v4/b1/c0/bc/b1c0bc66-9878-ba44-cc4f-13d6fa66c941/mza_3963905128460450707.jpg/100x100bb.jpg)
From the helm: Clarity Pharmaceuticals, Executive Chairman, Alan Taylor
Between the Bells
English - May 24, 2024 01:00 - 16 minutes - 11.2 MBInvesting Business online share trading trading ausbiz asx200 investing economics Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Weekly Wrap 17 May
Next Episode: Weekly Wrap 31 May
Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.
Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.
In this video Dr. Alan discusses: